Barinthus Biotherapeutics PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Barinthus Bio to Merge with Clywedog, Shifts Focus to Autoimmune Diseases Amidst Rising Losses
Barinthus Biotherapeutics plc announced a definitive all-stock merger agreement with Clywedog Therapeutics, Inc., refocusing its pipeline on immunology and inflammation while reporting increased net losses and a Nasdaq listing deficiency.
NASDAQ
Barinthus Biotherapeutics plc files its annual report on Form 10-K, highlighting pipeline prioritization and financial results for the year ended December 31, 2024.
NASDAQ
10-K: Barinthus Bio Reports Full Year 2023 Results, Highlights Pipeline Progress and Strategic Milestones
Barinthus Bio's 2023 annual report highlights significant progress in its clinical pipeline, strategic partnerships, and financial objectives, positioning the company for future growth.